Table 1.
Showed clinical characteristics of studied patients with COVID-19 under tocilizumab or pulse Dexamethasone therapy.
| COVID-19 patients under tocilizumab Therapy | COVID-19 patients under pulse Dexamethasone Therapy | P value | |
|---|---|---|---|
| Number | 46 | 63 | |
| The median age (IQR [interquartile range]) / years | 60.5 (49.5, 66.5) | 64 (55, 72) | 0.056 |
| Sex (male / female) | (26/ 20) | (36/ 27) | 0.948 |
| PaO2/FiO2 before treatment median (IQR) | 84 (75.75, 96.25) | 82 (70, 90) | 0.2 |
| PaO2/FiO2 2 days after treatment median (IQR) | 82 .2 (78, 124) | 92 (71, 129) | 0.344 |
| Neutrophiles/ Lymphocytes ratio median (IQR) | 3.72 (3.62, 4.11) | 3.69 (3.1, 3.69) | 0.057 |
| D-dimer ng/mL median (IQR) | 1420 (420, 3720) | 1400 (750, 3200) | 0.897 |
| Ferritin ng/mL median (IQR) | 1153.5 (661, 1562.5) | 934 (623, 1357) | 0.124 |
| NIV/ MV | 32/14 | 38/25 | 0.32 |
| CT Chest | |||
| GGO/Consolidation | 16/30 | 20/43 | 0.448 |
| Vasopressor before treatment | 28 | 27 | 0.081 |
| Comorbidities number (%) | |||
| Diabetes mellites | 16 (34.8%) | 15 (23.8%) | 0.149 |
| Hypertension | 26 (56.5%) | 26 (41.3%) | 0.84 |
| Heart diseases | 0 | 14 (22.2%) | < 0.0001 |
| Kidney disease | 4 (8.7%) | 5 (7.9%) | 0.576 |
| Cancer | 0 | 1 (1.6%) | 0.578 |
| Hyperthyroidism | 0 | 1 (1.6%) | 0.578 |
| hepatitis C virus | 2 (4.3%) | 2 (3.2%) | 0.565 |
| COPD | 0 | 2 (3.2%) | 0.332 |
| Asthma | 0 | 3 (4.8%) | 0.189 |
| Deaths number (%) | 32 (69.6%) | 33 (52.4%) | 0.05 |
| Nasocomial pneumonia | 14 (30.4%) | 16 (25.4%) | 0.356 |
| Hyper glycemia | 6 (13%) | 9 (14.3%) | 0.542 |
| Renal impairment | 3 (6.5%) | 2 (3.2%) | 0.353 |
| Increased liver enzymes | 6 (13%) | 5 (7.9%) | 0.288 |
| Pulmonary embolism | 3 (6.5%) | 1 (1.6%) | 0.201 |
Abbreviations MV: mechanical ventilation; NIV: Non-invasive ventilation; PaO2/FiO2: ratio of partial pressure of arterial oxygen over fraction of inspired oxygen; P ˂ 0.05 considered statistically significant. GGO ground glass opacities.